Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A novel recombinant basic fibroblast growth factor and its secretion.

Y D Sohn1, H J Lim, K C Hwang

  • 1Cardiovascular Research Institute, Yonsei University, Seoul, 120-752, Korea.

Biochemical and Biophysical Research Communications
|June 21, 2001
PubMed
Summary

A novel recombinant FGF-2 (4sFGF-2) was engineered for enhanced secretion, maintaining biological activity for potential gene therapy applications in angiogenesis and wound healing.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after two or more HER2-directed therapies.

ESMO open·2026
Same author

Exploring Dentists' Views on Professionalism and Identity Formation: A Template Analysis Study.

JDR clinical and translational research·2026
Same author

Systemic adjuvant and perioperative chemotherapy following curative-intent liver metastasectomy in colorectal cancer-is it justified?

ESMO gastrointestinal oncology·2026
Same author

Identifying predictive markers of head and neck squamous cell carcinoma in an umbrella trial (KCSG HN 15-16 TRIUMPH trial).

ESMO open·2025
Same author

Psychiatric disorders in adolescent and young adult cancer survivors in Korea.

ESMO open·2025
Same author

Efficacy and safety of home-based transcranial direct current stimulation as adjunct treatment for cognitive improvement in major depressive disorder: A double-blind, randomized, multi-site clinical trial.

European psychiatry : the journal of the Association of European Psychiatrists·2025

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Biotechnology

Background:

  • Basic fibroblast growth factor (FGF-2) is crucial for cell growth, differentiation, migration, and survival.
  • Clinical applications of FGF-2 gene transfer are explored for wound healing and ischemia treatment.
  • Native FGF-2 lacks a secretion signal peptide, limiting its therapeutic delivery.

Purpose of the Study:

  • To engineer a novel recombinant FGF-2 (4sFGF-2) with improved secretion.
  • To evaluate the biological activity and secretion efficiency of 4sFGF-2.
  • To assess the potential clinical applicability of 4sFGF-2 in gene transfer.

Main Methods:

  • A recombinant 4sFGF-2 was constructed by replacing the N-terminus of FGF-2 with a signal peptide from FGF-4.
  • The recombinant gene was expressed in COS-7 cells using a CMV promoter.

Related Experiment Videos

  • Biological activity was assessed by measuring DNA synthesis, cell growth, and MAPK activation in rat aortic smooth muscle cells and NIH3T3 cells.

    • Main Results:

    • The recombinant 4sFGF-2 was highly secreted into the culture media.
    • Secreted 4sFGF-2 demonstrated comparable biological activity to native FGF-2.
    • 4sFGF-2 effectively activated MAPK signaling in rat aortic smooth muscle cells.

    Conclusions:

    • The novel 4sFGF-2 exhibits enhanced secretion and retains biological function.
    • 4sFGF-2 holds promise for clinical applications in angiogenic growth factor gene transfer.
    • This engineered FGF-2 variant could advance therapeutic strategies for ischemic diseases and wound healing.